Adults taking tirzepatide lose an average of 15 kilograms over six months while experiencing a 35% reduction in fat mass and preserving skeletal muscle. A study published in the Journal of Diabetes and Its Complications tracked 122 overweight and obese patients in Palermo, Italy, to measure real-world changes in body composition and metabolic health.
Patient demographics and clinical characteristics of study participants
Researchers examined 122 adults treated at two clinical centers in Palermo, Italy. The cohort had a mean age of 44 years and consisted mostly of women, at 79.5%. At baseline, 78% of participants were classified with obesity and 93% were non-smokers. Comorbidities within the group included 19% with hypertension, 15.6% with prediabetes, 15% with dyslipidemia, and 4% with obstructive sleep apnea. Patients with type 2 diabetes were excluded from the analysis.
Participants initiated tirzepatide at a dose of 2.5 milligrams once weekly, which increased to 5 milligrams after four weeks. Patients followed a low-carbohydrate diet without a prescribed caloric restriction for the 24-week duration. They also engaged in tailored physical activity. Individuals under 50 without comorbidities performed aerobic and resistance training, while participants aged 50 and older or those with comorbidities completed at least 150 minutes of moderate-intensity aerobic activity weekly.
Body Composition and Weight Loss Outcomes
Anthropometric measures decreased significantly at 12 and 24 weeks compared to baseline. At the 12-week mark, 86% of participants achieved a weight loss of at least 5%, while 41% lost at least 10%. By 24 weeks, those proportions rose: 98% of participants lost at least 5%, 89% lost at least 10%, 72% lost at least 15%, and 59% lost at least 20%. Average reductions in body mass index, waist circumference, and waist-to-height ratio reached 15.7%, 14.9%, and 15.2% respectively.
Fat mass declined by 35.4% from baseline, and fat-free mass decreased by 5.1%. Skeletal muscle mass remained stable throughout the 24 weeks. Average weight loss reached 15 kilograms, with an average tirzepatide dose of 5.3 milligrams. Fasting plasma glucose, fasting insulin levels, and HOMA-IR insulin resistance values all improved over the study period, with changes in body mass index, weight, and fat mass positively associated with improvements in insulin sensitivity.
Clinical Limitations and Methodology
The study relied on a retrospective design and lacked a control arm. This structure makes it difficult to separate the effects of tirzepatide from the accompanying diet and physical activity interventions. Researchers only analyzed patients who completed the full 24-week follow-up, which may have influenced overall effectiveness estimates.
Body composition was assessed using bioelectrical impedance analysis under routine clinical conditions. The predominance of female participants may limit the generalizability of the body composition findings to broader populations. Systematic data on treatment persistence and adverse events were unavailable, and the study was conducted in a single geographic area, requiring further research in diverse clinical groups.
Frequently Asked Questions
What is tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist designed to reduce weight and improve metabolic outcomes.
What dose of tirzepatide did participants take?
Patients started at 2.5 milligrams once weekly, increasing to 5 milligrams after four weeks, with an overall average dose of 5.3 milligrams over the 24-week study period.
How much skeletal muscle did patients lose?
Skeletal muscle mass remained stable throughout the 24-week treatment period while fat mass declined by 35.4%.
Related reading